Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.

CONCLUSIONS: Based on the main comparisons, we did not find consistent evidence that H1 AH treatments are effective as 'add-on' therapy for eczema when compared to placebo; evidence for this comparison was of low and moderate quality. However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares. Cetirizine was no better than placebo in terms of physician-assessed clinical signs nor patient-assessed symptoms, and we found no evidence that loratadine was more beneficial than placebo, although all interventions seem safe.The quality of evidence was limited because of poor study design and imprecise results. Future researchers should clearly define the condition (course and severity) and clearly report their methods, especially participant selection and randomisation; baseline characteristics; and outcomes (based on the Harmonising Outcome Measures in Eczema initiative). PMID: 30666626 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research

Related Links:

I recently learned that a popular EM Twitter doc runs a headache clinic on the side. In conjunction with the constant threads and talks about the very real and understandable burnout in EM, I've begun thinking long-term about the implications of pursuing the specialty if I choose to do so. One area that is hard for me to get good insight and data on is on what being an EP would look like once past 50 or even 60 years of age. I am hoping for some insight from this community on this topic... M3 interested in EM: Do you plan on practicing into your late 50s or 60s?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Emergency Medicine Source Type: forums
Publication date: January 2020Source: The Lancet Neurology, Volume 19, Issue 1Author(s): Gisela M Terwindt
Source: The Lancet Neurology - Category: Neurology Source Type: research
Conclusions: Our data support the hypothesis that increased anxiety may play a role in visuo-vestibular interactions; moreover, they are not inconsistent with the hypothesis that OKS might provoke a “threatening effect,” leading to gaze bias during examination.
Source: Otology and Neurotology - Category: ENT & OMF Tags: VESTIBULAR DISORDERS Source Type: research
Conditions:   Sepsis;   Septic Shock Interventions:   Drug: Vitamin C;   Drug: Hydrocortisone;   Drug: Complex B Sponsor:   IMSS Hospital General de Zona 11, Piedras Negras Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Migraine;   Vestibular Migraine;   Vestibular Schwannoma;   Motion Sickness;   Dizziness;   Vestibular Disorder Interventions:   Behavioral: Temporal Binding Adaptation - TBW training;   Behavioral: Temporal Binding Adaptation - PSS training;   Behavioral: Temporal Binding Adaptation - PSS adaptation with VI stimulation;   Behavioral: Chronic Motion-modulated Stimulation Sponsors:   Massachusetts Eye and Ear Infirmary;   National Institute on Deafness and Other Communication Disorders (NIDCD); &n...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Headache Disorders;   Tension-Type Headache Intervention:   Other: Bite force testing Sponsors:   Danish Headache Center;   UMC Utrecht;   Academic Centre for Dentistry in Amsterdam Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Atopic Dermatitis Intervention:   Drug: Upadacitinib Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Concussion;   mTBI;   Post-Concussive Symptoms;   Chronic Headache;   Chronic Insomnia;   Chronic Attention Disorder Intervention:   Procedure: Neurofeedback (NFB) Sponsor:   VA Office of Research and Development Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
New guidelines on pharmacological treatment for pediatric migraine underscore the need for more research to help the one-third of children and adolescents who aren't helped by existing treatments, according to the authors of a new report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
Migraine is a huge medical problem, accounting for half of the disability produced by all neurologic diseases worldwide. The medication sumatriptan (Imitrex) is well known for the treatment of a migraine attack. Sumatriptan is part of a group of medications known as the triptans. Triptan medications have been in use for over 20 years and are very effective for the acute treatment of headache (relieving migraine headaches that are already in progress). But they also have limitations; triptans can cause temporary narrowing of blood vessels in the heart and elsewhere that can result in side effects, such as chest pain or tigh...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Drugs and Supplements Headache Health Source Type: blogs
More News: Allegra | Children | Conferences | Databases & Libraries | Dermatitis | Dermatology | Eczema | Fexofenadine | General Medicine | Headache | Hydrocortisone | Insomnia | Itchiness | Migraine | Respiratory Medicine | Skin | Statistics | Study | Zyrtec